Note: Ingredients listed on restricted chemical lists
EC/CAS
13463-67-7
Name of the chemical
Reaction mass of titanium dioxide and silver chloride
Concentration
>=0.1-<1
General Information
Version
3.5
Revision date
2017-05-02
Product name
Montelukast Tablet Formulation
supplier name
Merck & Co., Inc
Emergency telephone
1-908-423-6000
Icons in SDS
Company Information
company name
Merck & Co., Inc
e-mail address of the competent person responsible for the Safety Data Sheet
EHSDATASTEWARD@merck.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H351
Hazard statements
Code
Statements
H351
Suspected of causing cancer
Section 2
SECTION 2: Hazards identification
29 CFR 1910.1200) GHS classification in accordance with
Signal word
Warning
Hazard statements
If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air. H351 Suspected of causing cancer if inhaled.
Prevention
P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Storage
P405 Store locked up.
Disposal
P501 Dispose of contents/ container to an approved waste dis- posal plant.
2.3 Other hazards
Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin.
